E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10025140 |
E.1.2 | Term | Lupus nephritis |
E.1.2 | System Organ Class | 10038359 - Renal and urinary disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the long-term safety and tolerability of Orelvo compared with placebo for up to an additional 24 months following completion of treatment in the AURORA 1 study in subjects with lupus nephritis (LN). |
|
E.2.2 | Secondary objectives of the trial |
To assess the long-term efficacy of Orelvo compared with placebo for up to an additional 24 months following completion of treatment in the AURORA 1 study in subjects with LN |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Written informed consent before any study-specific procedures are performed.
2.Male or female subjects who have completed 52 weeks of treatment with study drug in the AURORA 1 study. Subjects who had a temporary interruption and successfully restarted study drug during the AURORA 1 study will be allowed with Medical Monitor approval.
3.In the opinion of the Investigator, subject requires continued immunosuppressive therapy.
4.Women of childbearing potential must continue to use effective contraception and have a negative urine pregnancy test at Month 12. Two effective forms of contraception must be used simultaneously unless abstinence is the chosen method. Subjects must use effective contraception during the study (see Protocol Section 5.4, Adequate/Effective Contraception).
5.Subject is willing to continue taking oral MMF for the duration of the study. |
|
E.4 | Principal exclusion criteria |
1.Subjects unable or unwilling to give written informed consent and/or to comply with study procedures.
2.Currently taking or known need for any of the medications or food items listed in Protocol Section 7.8, Prohibited Therapy and Concomitant Treatment during the study.
3.Subjects currently requiring renal dialysis (hemodialysis or peritoneal dialysis) or expected to require dialysis during the study period.
4.A planned kidney transplant within study treatment period.
5.Subjects with any medical condition which, in the Investigator’s judgment, may be associated with increased risk to the subject or may interfere with study assessments or outcomes.
6.Subjects who are pregnant, breast feeding or, if of childbearing potential, not using adequate contraceptive precautions.
7.Vaccines using live organisms, virus or bacterial, while taking the study treatment.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Adverse events (AE) profile and routine biochemical and hematological assessments. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At the end of the study, but as part of that analysis, it will be looked at each study visit. |
|
E.5.2 | Secondary end point(s) |
- Proportion of subjects in renal response defined as:
· UPCR of ≤0.5 mg/mg
· estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR of >20%
· Received no rescue medication for LN
· Did not receive more than 10 mg prednisone for ≥3 consecutive days or for ≥7 days in total during the 8 weeks prior to the renal response assessment.
- Subjects who withdraw from the study prior to the response assessment will be defined as non-responders.
- Proportion of subjects in partial renal response defined as a 50% reduction from baseline in UPCR.
- Renal flare as adjudicated by the Clinical Endpoints Committee (CEC).
- Extra-renal flare as adjudicated by the CEC.
- SELENA-SLEDAI scores by visit.
- Change in UPCR, eGFR, urine protein, and serum creatinine from AURORA 1 baseline.
- Change in immunology parameters (complement 3 (C3), complement 4 (C4), and anti double-stranded deoxyribonucleic acid (DNA)) from AURORA 1 baseline.
- Change in health-related quality of life (HRQoL) (SF-36) from AURORA 1 baseline.
- Healthcare Resource Utilization (HRU).
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
• Change in UPCR, eGFR, urine protein, and serum creatinine from AURORA 1 baseline at each visit.
• Change in immunology parameters (C3, C4, and anti-dsDNA) from AURORA 1 baseline at each visit.
• Change in HRQoL (SF-36) from AURORA 1 baseline at Months 12, 18, 24, 30, and 36.
• Change in SELENA-SLEDAI scores by visit at Months 12, 18, 24, and 36.
• Healthcare Resource Utilization at Months 12, 15, 18, 21, 24, 27, 30, 33, and 36. Key aspects will be summarized by visit and changes over time will be explored
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 19 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belarus |
Brazil |
Bulgaria |
Canada |
Chile |
Colombia |
Costa Rica |
Croatia |
Dominican Republic |
Guatemala |
Japan |
Korea, Republic of |
Macedonia, the former Yugoslav Republic of |
Malaysia |
Mexico |
Netherlands |
Peru |
Philippines |
Poland |
Puerto Rico |
Russian Federation |
Serbia |
South Africa |
Spain |
Sri Lanka |
Taiwan |
Thailand |
Turkey |
Ukraine |
United States |
Vietnam |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 15 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 15 |
E.8.9.2 | In all countries concerned by the trial days | 0 |